Drug Profile
Prolgolimab - Biocad
Alternative Names: Anti PD-1 mAb; Anti-PD-1 monoclonal antibody; BCD-100 - Biocad; FortecaLatest Information Update: 04 Jul 2023
Price :
$50
*
At a glance
- Originator Biocad
- Developer Biocad; Pavlov First State Medical University of Saint Petersburg; SPH-BIOCAD
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Malignant melanoma
- Phase III Cervical cancer; Non-small cell lung cancer
- Phase II Hodgkin's disease
- No development reported Solid tumours
Most Recent Events
- 02 Jun 2023 Interim safety and efficacy data from a phase II CAESURA trial presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 10 Mar 2023 Phase-II clinical trials in Hodgkin's disease (Combination therapy, In adults, In the elderly, Second-line therapy or greater) in Russia (IV) (NCT05757466)
- 10 Mar 2023 Phase-II clinical trials in Hodgkin's disease (Second-line therapy or greater, Monotherapy, In adults, In the elderly) in Russia (IV) (NCT05757466)